Overexpression of CD99 Increases the Migration and Invasiveness of Human Malignant Glioma Cells

Genes and Cancer

Volumn 3, Issue 9-10, 2012, Pages 535-549

  Seol, Ho Jun ^a,b   Chang, Jong Hee ^a,c   Yamamoto, Junkoh ^a,d   Romagnuolo, Rocco ^a   Suh, Youngchul ^a,e   Weeks, Adrienne ^a   Agnihotri, Sameer ^a   Smith, Christian A ^a   Rutka, James T ^a,f  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e Yonsei University College of Medicine   (South Korea)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

amoeboid; CD99; glioma; invasion; mesenchymal; migration

Indexed keywords

CD99 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAC PROTEIN; RHO FACTOR; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

AMOEBOID MESENCHYMAL TRANSITION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MESENCHYME CELL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE MICROARRAY; WESTERN BLOTTING; WILD TYPE;

EID: 84875510616     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912473603     Document Type: Article

References (36)

1. Burger PC.The "ideal" classification of pediatric central nervous system neoplasms.Cancer. 1985;56:1865-8.
2. Giese A.Glioma invasion-pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and proto-oncogene ETS-1.Acta Neurochir Suppl. 2003;88:153-62.
3. Lauffenburger DA.Cell motility: making connections count.Nature. 1996;383 (6599): 390-1.
4. Ohta Y,Hartwig JH,Stossel TP.FilGAP, a Rho- and ROCK-regulated GAP for Rac binds filamin A to control actin remodelling.Nat Cell Biol. 2006;8 (8): 803-14.
5. Sahai E,Marshall CJ.Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.Nat Cell Biol. 2003;5 (8): 711-9.
6. Sanz-Moreno V,Gadea G,Ahn J, et al.Rac activation and inactivation control plasticity of tumor cell movement.Cell. 2008;135 (3): 510-23.
7. Demuth T,Berens ME.Molecular mechanisms of glioma cell migration and invasion.J Neurooncol. 2004;70 (2): 217-28.
8. Mitchison TJ,Cramer LP.Actin-based cell motility and cell locomotion.Cell. 1996;84 (3): 371-9.
9. Persson O,Krogh M,Saal LH, et al.Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets.J Neurooncol. 2007;85 (1): 11-24.
10. Levy R,Dilley J,Fox RI,Warnke R.A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies.Proc Natl Acad Sci U S A. 1979;76 (12): 6552-6.
11. Hamilton G,Fellinger EJ,Schratter I,Fritsch A.Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen.Cancer Res. 1988;48 (21): 6127-31.
12. Kovar H,Dworzak M,Strehl S, et al.Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor.Oncogene. 1990;5 (7): 1067-70.
13. Gelin C,Aubrit F,Phalipon A, et al.The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product.EMBO J. 1989;8 (11): 3253-9.
14. Weidner N,Tjoe J.Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma.Am J Surg Pathol. 1994;18 (5): 486-94.
15. Byun HJ,Hong IK,Kim E, et al.A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways.J Biol Chem. 2006;281 (46): 34833-47.
16. Scotlandi K,Baldini N,Cerisano V, et al.CD99 engagement: an effective therapeutic strategy for Ewing tumors.Cancer Res. 2000;60 (18): 5134-42.
17. Scotlandi K,Zuntini M,Manara MC, et al.CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity.Oncogene. 2007;26 (46): 6604-18.
18. Manara MC,Bernard G,Lollini PL, et al.CD99 acts as an oncosuppressor in osteosarcoma.Mol Biol Cell. 2006;17 (4): 1910-21.
19. Kreppel M,Aryee DN,Schaefer KL, et al.Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells.Oncogene. 2006;25 (19): 2795-800.
20. Hahn JH,Kim MK,Choi EY, et al.CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion.J Immunol. 1997;159 (5): 2250-8.
21. Dworzak MN,Froschl G,Printz D, et al.CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.Leukemia. 2004;18 (4): 703-8.
22. Fisher C.Synovial sarcoma.Ann Diagn Pathol. 1998;2 (6): 401-21.
23. Brown RE,Boyle JL.Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications.Ann Clin Lab Sci. 2003;33 (2): 131-41.
24. Ramani P,Rampling D,Link M.Immunocytochemical study of 12E7 in small round-cell tumours of childhood: an assessment of its sensitivity and specificity.Histopathology. 1993;23 (6): 557-61.
25. Pelosi G,Fraggetta F,Sonzogni A,Fazio N,Cavallon A,Viale G.CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours.Virchows Arch. 2000;437 (3): 270-4.
26. Maitra A,Hansel DE,Argani P, et al.Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays.Clin Cancer Res. 2003;9 (16): 5988-95.
27. Jung KC,Park WS,Bae YM, et al.Immunoreactivity of CD99 in stomach cancer.J Korean Med Sci. 2002;17 (4): 483-9.
28. Milanezi F,Pereira EM,Ferreira FV,Leitao D,Schmitt FC.CD99/MIC-2 surface protein expression in breast carcinomas.Histopathology. 2001;39 (6): 578-83.
29. Wolf RM,Draghi N,Liang X, et al.p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3.Genes Dev. 2003;17 (4): 476-87.
30. Kakinuma N,Roy BC,Zhu Y,Wang Y,Kiyama R.Kank regulates RhoA-dependent formation of actin stress fibers and cell migration via 14-3-3 in PI3K-Akt signaling.J Cell Biol. 2008;181 (3): 537-49.
31. Nishioka T,Nakayama M,Amano M,Kaibuchi K.Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3zeta affinity chromatography.Cell Struct Funct. 2012;37 (1): 39-48.
32. Kurokawa K,Matsuda M.Localized RhoA activation as a requirement for the induction of membrane ruffling.Mol Biol Cell. 2005;16 (9): 4294-303.
33. Wang HR,Zhang Y,Ozdamar B, et al.Regulation of cell polarity and protrusion formation by targeting RhoA for degradation.Science. 2003;302 (5651): 1775-9.
34. Hwang JH,Smith CA,Salhia B,Rutka JT.The role of fascin in the migration and invasiveness of malignant glioma cells.Neoplasia. 2008;10 (2): 149-59.
35. Salhia B,Rutten F,Nakada M, et al.Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1.Cancer Res. 2005;65 (19): 8792-800.
36. Valster A,Tran NL,Nakada M,Berens ME,Chan AY,Symons M.Cell migration and invasion assays.Methods. 2005;37 (2): 208-15.